Latest Breaking News On - Major adverse cardiac event - Page 1 : comparemela.com

Mesoblast Reports Operational and Financial Highlights for

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United kingdomUnited statesSteve dabkowskiPaul hughesResearch developmentMarrow transplant researchAustralian securities exchangeCorporate communications investorsPharmaceuticals coJournal of the american college cardiologyDrug administrationMesoblast limited nasdaqBiologics license applicationPrescription drug user fee actPre license inspectionFood drug

Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023

26.05.2023 - NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March .

United statesUnited kingdomPaul hughesSteve dabkowskiPharmaceuticals coDrug administrationAustralian securities exchangeMarrow transplant researchResearch developmentCorporate communications investorsJournal of the american college cardiologyBiologics license applicationPrescription drug user fee actPre license inspectionFood drugCosmetic act

Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023

Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSteve dabkowskiPaul hughesCorporate communications investorsPharmaceuticals coMarrow transplant researchResearch developmentMesoblast limited nasdaqAustralian securities exchangeDrug administrationJournal of the american college cardiologyBiologics license applicationPrescription drug user fee actPre license inspectionFood drug

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology

Single Intra-Myocardial Intervention with Rexlemestrocel-L Reduced Cardiovascular Death, Myocardial Infarction or Stroke Over Mean Follow-Up of 30 Months in High-Risk Patients with Chronic Heart Failure

United statesJosephg rogersSilviu itescuEmersonc perinTexas heart instituteCardiology researchCardiothoracic surgical trials networkUnited network for organEuropean society of cardiologyJournal of the american college cardiologyUs food drug administrationAgency for healthcare researchMesoblast limitedAmerican collegeMedical directorNorth america

Mesoblast (MESO) Announces DREAM-HF Phase 3 Trial Results for Cell Therapy in Heart Failure Published in JACC

Mesoblast (MESO) Announces DREAM-HF Phase 3 Trial Results for Cell Therapy in Heart Failure Published in JACC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJosephg rogersSilviu itescuEmersonc perinTexas heart instituteYork heart associationCardiology researchCardiothoracic surgical trials networkJournal of the american college cardiologyMesoblast limited nasdaqUs food drug administrationAmerican collegeMedical directorNorth americaMajor adverse cardiac eventAmerican heart journal plus